GlassScriptPhysician profile
Craig D Robison
NPI 1528367307
$4,475.04
in general payments reported to CMS, 2019-2025
24 companies · $1,001 in 2025
The $1,001 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $530 · 2020: $165 · 2021: $679 · 2022: $656 · 2023: $469 · 2024: $975 · 2025: $1,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,426 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,426.45 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $1,649.00 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Abiomed | $382.52 | 2019-2025 | |
| Abbott Laboratories | $366.78 | 2019-2025 | Ensite |
| Astrazeneca Pharmaceuticals LP | $299.12 | 2019-2025 | Wainua, Farxiga |
| Boston Scientific Corporation | $261.92 | 2020-2024 | Watchman Flx |
| Ekos Corporation | $214.21 | 2019 | |
| United Therapeutics Corporation | $204.58 | 2023-2025 | Tyvaso, Tyvaso |
| Medtronic, INC. | $179.30 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $136.66 | 2024 | Winrevair |
| Terumo Medical Corporation | $123.59 | 2021 | |
| Novartis Pharmaceuticals Corporation | $118.72 | 2025 | |
| Biosense Webster, INC. | $116.69 | 2022 | |
| Johnson & Johnson Health Care Systems INC. | $88.87 | 2024 | Uptravi, Opsumit |
| Bridgebio Pharma, INC. | $81.15 | 2025 | Attruby |
| Bard Peripheral Vascular, INC. | $58.81 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $48.76 | 2024-2025 | Assure Wcd |
| Pfizer INC. | $24.85 | 2022 | |
| Sandoz INC. | $23.13 | 2025 | Treprostinil |
| Cvrx, INC. | $22.09 | 2024 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $16.79 | 2025 | |
| Philips North America LLC | $15.19 | 2022 | |
| Alnylam Pharmaceuticals INC. | $14.41 | 2025 | Amvuttra |
| Inspire Medical Systems, INC. | $14.36 | 2024 | Inspire |
| Medtronic Vascular, INC. | $13.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Robison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.